查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1304270

藥物輸送和遺傳基因通知設備市場:各產品，成藥，各地區:規模，佔有率，展望，機會分析，2023年～2030年

Drug and Gene Delivery Devices Market, By Product, By Commercialized Drugs (Luxturna, Yescarta, Zolgensma, Kymriah, Provenge, and Strimvelis ), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態:

傳染病、心血管疾病、癌症和糖尿病等慢性病負擔的不斷增加，對藥物輸送和基因輸送設備的需求不斷增加，細胞和基因治療的資金增加，以及基因治療的批准增加，這些是預計的關鍵因素。在預測期內增強全球藥物輸送和基因輸送設備市場的增長。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球藥物輸送和遺傳基因通知設備市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球藥物輸送和遺傳基因通知設備市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球藥物輸送和遺傳基因通知設備市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球藥物輸送和遺傳基因通知設備市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概況

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
  • 連貫·機遇·地圖(COM)

第3章 市場動態，法規，趨勢分析

  • 市場動態
    • 全球慢性病負擔增加
    • 嚴格的規章制度
    • 對藥物和基因輸送設備的需求不斷增加
  • 影響分析
  • 主要的焦點
  • 法規情勢
  • 產品上市/核准
  • PEST分析
  • 波特分析
  • 合併·收購情勢

第4章 藥物輸送和遺傳基因通知設備的全球市場-冠狀病毒(COVID-19)流行的影響

  • COVID-19流行病學
  • 供給面和需求面的分析
  • 經濟影響

第5章 藥物輸送和遺傳基因通知設備的全球市場:各產品，2018-2030年

  • 視網膜下注射導管
  • 延長管
  • 靜脈導管
  • 殺菌胰島素注射器
  • 預填充式注射器
  • 輸液袋子

第6章 藥物輸送和遺傳基因通知設備的全球市場:成藥，2018年～2030年

  • Luxturna(藥物輸送設備)
  • Yescarta（藥物輸送裝置）
  • Zolgensma（藥物輸送裝置）
  • Kymriah（藥物輸送裝置）
  • Provenge（藥物輸送裝置）
  • Strimvelis（藥物輸送裝置）

第7章 藥物輸送和遺傳基因通知設備的全球市場:各地區，2018年～2030年

  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭情形

  • Pfizer, Inc.
  • Novartis AG
  • Kite Pharma, Inc.
  • Bluebird bio, Inc.
  • Vericel Corporation
  • uniQure N.V.
  • Spark Therapeutics, Inc.
  • Renova Therapeutics
  • Orchard Therapeutics plc
  • Kolon Tissue Gene, Inc.
  • Human Stem Cell Institute
  • Amgen, Inc.
  • Dendreon Pharmaceuticals
  • Helixmith Co.
  • Bausch & Lomb Incorporated, Ltd.(ViroMed Co., Ltd.)
  • Becton Dickinson and Company
  • Castle Creek Biosciences, Inc.(Fibrocell Technologies, Inc.)

第9章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI5864

The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.

Market Dynamics:

Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devices market over the forecast period.

For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key features of the study:

  • This report provides in-depth analysis of the global drug and gene delivery devices market, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global drug and gene delivery devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global drug and gene delivery devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devices market.

Detailed Segmentation:

  • Global Drug and Gene Delivery Devices Market, By Product:
    • Sub-retinal Injection Cannula
    • Extension Tube
    • Intravenous Catheter
    • Sterile Insulin Syringe
    • Pre-filled Syringe
    • Infusion Bags
  • Global Drug and Gene Delivery Devices Market, By Commercialized Drugs:
    • Luxturna (Drug Delivery Devices)
    • Yescarta (Drug Delivery Devices)
    • Zolgensma (Drug Delivery Devices)
    • Kymriah (Drug Delivery Devices)
    • Provenge (Drug Delivery Devices)
    • Strimvelis (Drug Delivery Devices)
  • Global Drug and Gene Delivery Devices Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer, Inc.
    • Novartis AG
    • Kite Pharma, Inc.
    • Bluebird bio, Inc.
    • Becton Dickinson and Company
    • Amgen, Inc.
    • Vericel Corporation
    • uniQure N.V.
    • Spark Therapeutics, Inc.
    • Renova Therapeutics
    • Orchard Therapeutics plc
    • Kolon Tissue Gene, Inc.
    • Human Stem Cell Institute
    • Dendreon Pharmaceuticals
    • Helixmith Co., Ltd (ViroMed Co., Ltd.)
    • Bausch & Lomb Incorporated
    • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product
    • Market Snapshot, By Commercialized Drugs
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of chronic diseases across the globe
    • Stringent rules and regulations
    • Increasing demand for drug and gene delivery devices
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Drug and Gene Delivery Devices Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Drug and Gene Delivery Devices Market, By Product, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Sub-retinal Injection Cannula
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Extension Tube
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Intravenous Catheter
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Sterile Insulin Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Pre-filled Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Infusion Bags
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

6. Global Drug and Gene Delivery Devices Market, By Commercialized Drugs, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Luxturna (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Yescarta (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Zolgensma (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Kymriah (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Provenge (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Strimvelis (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

7. Global Drug and Gene Delivery Devices Market, By Region, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)

8. Competitive Landscape

  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kite Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bluebird bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vericel Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Renova Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orchard Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kolon Tissue Gene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Human Stem Cell Institute
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dendreon Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Helixmith Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch & Lomb Incorporated, Ltd. (ViroMed Co., Ltd.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us